Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio 45229, USA.
Nat Rev Drug Discov. 2013 Feb;12(2):117-29. doi: 10.1038/nrd3838. Epub 2013 Jan 21.
Eosinophils can regulate local immune and inflammatory responses, and their accumulation in the blood and tissue is associated with several inflammatory and infectious diseases. Thus, therapies that target eosinophils may help control diverse diseases, including atopic disorders such as asthma and allergy, as well as diseases that are not primarily associated with eosinophils, such as autoimmunity and malignancy. Eosinophil-targeted therapeutic agents that are aimed at blocking specific steps involved in eosinophil development, migration and activation have recently entered clinical testing and have produced encouraging results and insights into the role of eosinophils. In this Review, we describe recent advances in the development of first-generation eosinophil-targeted therapies and highlight strategies for using personalized medicine to treat eosinophilic disorders.
嗜酸性粒细胞可以调节局部免疫和炎症反应，其在血液和组织中的积累与几种炎症和感染性疾病有关。因此，针对嗜酸性粒细胞的治疗方法可能有助于控制多种疾病，包括特应性疾病（如哮喘和过敏）以及与嗜酸性粒细胞关系不大的疾病（如自身免疫和恶性肿瘤）。最近，针对阻断嗜酸性粒细胞发育、迁移和激活过程中特定步骤的靶向嗜酸性粒细胞治疗药物已经进入临床测试，并为嗜酸性粒细胞的作用提供了令人鼓舞的结果和见解。在这篇综述中，我们描述了第一代靶向嗜酸性粒细胞治疗方法的最新进展，并强调了使用个性化医疗治疗嗜酸性粒细胞疾病的策略。
